Categories: Web and IT News

Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients

— Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients.

SAINT LOUIS, Mo.–(BUSINESS WIRE)–Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, enabling physicians to use the test to help guide treatment decisions for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC). The successful readout is announced on the heels of the yearly national PREDAPT Summit, where the participating institutions from across the country gathered and reviewed the study results. The assay was validated in independent HNSCC patient cohorts receiving anti-PD-1 inhibitors pembrolizumab and nivolumab both as a single agent and in combination with chemotherapy. This milestone clears the assay for nationwide clinical use in an interventional setting where doctors can now incorporate OncoPrism to help guide patient treatment in a landscape of multiple therapies, each benefiting a subset of the patient population.

“This is a proud day for all those working tirelessly to bring precision medicine to immunotherapy and improve the outcome and quality of care for patients. We have learned not only from the study’s validation results but from physicians across the nation who have had significant input on the study and the OncoPrism assay these last 3 years,” stated Jarret Glasscock, Cofactor’s CEO.

This validation announcement follows a publication earlier this year in the Journal of Cancer Research and Clinical Oncology, where Cofactor along with more than 20 participating institutions reported on OncoPrism’s capability to predict HNSCC patients’ response to anti-PD-1 immune checkpoint inhibitors. Cofactor’s broader work, on the technology’s ability to predict response to immune checkpoint inhibitors (ICI) across multiple cancers, was recognized by the Nature Publishing Group as the second most downloaded oncology paper of the year.

While the validation of OncoPrism in HNSCC patients was the focus of this week’s announcement, Cofactor’s national PREDAPT clinical trial is aimed at evaluating OncoPrism in 11 cancers including lung, head and neck, colorectal, breast, cervical, liver, kidney, esophageal and bladder. US healthcare systems supporting and participating in the PREDAPT trial collectively provide care to approximately 20% of the total US patient population.

About Cofactor Genomics

Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Predicting patient response to therapy currently relies on isolated, single-analyte biomarkers that have failed to deliver accurate therapy response predictions, resulting in unnecessary healthcare costs, and most harmfully, negative outcomes for patients. Cofactor’s products use Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers to deliver on the promise of precision medicine.

Contacts

press@cofactorgenomics.com

The post Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients appeared first on Daily Host News.

Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients first appeared on Web and IT News.

awnewsor

Recent Posts

Shootbolt launches an instant part identifier for multipoint door locks

Shootbolt has launched a free online tool that identifies the replacement part for a multipoint…

2 hours ago

Prospect Markets Nominates VanEck Canada CEO Kevin Gopaul for Election to Board of Directors

table, td, td p, span, font {font-family: Arial, Helvetica, sans-serif ; font-size:11pt ;} View this…

5 hours ago

Bank Customers On the Hook if Third-Party AI Leads to Losses

Banks are changing their terms of service, with more saying customers will be on the…

5 hours ago

OpenAI Details AI’s Role In Chip Design

OpenAI has pulled back the curtains on the role AI is playing in designing Jalapeño,…

5 hours ago

Google Wallet Comes to iOS

Google announced Tuesday that its popular Google Wallet application is finally available on iOS in…

5 hours ago

Tesla Investing 3 Billion Euros In German Gigafactory Cybercab Production

Tesla is investing 3 billion euros to expand its Gigafactory in Berlin-Brandenburg to further facilitate…

5 hours ago

This website uses cookies.